Ligand Pharmaceuticals LGND Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other commercial liabilities?
- Ligand Pharmaceuticals (LGND) reported other commercial liabilities of $31.85M in Q1 2026.
- How has Ligand Pharmaceuticals's other commercial liabilities changed year-over-year?
- Ligand Pharmaceuticals's other commercial liabilities increased by 35.3% year-over-year, from $23.54M to $31.85M.
- What is the long-term trend for Ligand Pharmaceuticals's other commercial liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's other commercial liabilities has grown at a 11.2% compound annual growth rate (CAGR), from $18.53M to $31.45M.